Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Expected to Announce Earnings of -$0.30 Per Share

Wall Street analysts forecast that Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) will announce ($0.30) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Osmotica Pharmaceuticals’ earnings. Osmotica Pharmaceuticals posted earnings per share of ($4.99) during the same quarter last year, which would indicate a positive year-over-year growth rate of 94%. The company is expected to issue its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Osmotica Pharmaceuticals will report full year earnings of ($0.98) per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will post earnings of ($1.60) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.06. The company had revenue of $57.53 million for the quarter, compared to the consensus estimate of $57.90 million. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%.

Several equities analysts have commented on OSMT shares. Zacks Investment Research downgraded Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, September 7th. ValuEngine downgraded Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. Jefferies Financial Group set a $10.00 price target on Osmotica Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Osmotica Pharmaceuticals in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $13.00.

Shares of Osmotica Pharmaceuticals stock opened at $4.12 on Monday. The stock’s fifty day moving average is $3.85 and its two-hundred day moving average is $3.44. The company has a market capitalization of $178.26 million and a PE ratio of -8.08. The company has a quick ratio of 1.49, a current ratio of 1.78 and a debt-to-equity ratio of 1.05. Osmotica Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $9.75.

Several institutional investors and hedge funds have recently bought and sold shares of OSMT. Acadian Asset Management LLC lifted its stake in shares of Osmotica Pharmaceuticals by 277.5% during the 2nd quarter. Acadian Asset Management LLC now owns 53,846 shares of the company’s stock worth $206,000 after purchasing an additional 39,584 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Osmotica Pharmaceuticals by 5.6% during the 2nd quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock worth $378,000 after purchasing an additional 5,230 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in shares of Osmotica Pharmaceuticals by 107.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 525,198 shares of the company’s stock worth $1,996,000 after purchasing an additional 272,109 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Osmotica Pharmaceuticals during the 2nd quarter worth $142,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Osmotica Pharmaceuticals during the 2nd quarter worth $120,000. 6.93% of the stock is currently owned by institutional investors and hedge funds.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Featured Story: What is a blue-chip stock?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.